Skip to content

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
5.8×+0.3×
PTC Therapeutics logo
PTC TherapeuticsPTCT
2.4×-1.5×
Insmed logo
InsmedINSM
4.5×-1.4×
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
8.4×+1.9×

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.82B-63.1%
Enterprise value$1.56B-67.2%
P/S0.8×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×

Where this comes from

Calculated from Sarepta Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s current ratio?
Sarepta Therapeutics, Inc. (SRPT) reported current ratio of 4.6× in Q1 2026.
How has Sarepta Therapeutics, Inc.'s current ratio changed year-over-year?
Sarepta Therapeutics, Inc.'s current ratio increased by 15.2% year-over-year, from 4× to 4.6×.
What is the long-term trend for Sarepta Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s current ratio has grown at a -17.3% compound annual growth rate (CAGR), from 6× to 2.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.